Combining BET protein inhibitors with radiation in HPV oropharyngeal cancer
BET 蛋白抑制剂与放射治疗 HPV 口咽癌的联合治疗
基本信息
- 批准号:10578185
- 负责人:
- 金额:$ 21.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-12-08 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressApoptosisBloodBromodomainBromodomains and extra-terminal domain inhibitorCancer EtiologyCell CycleCell LineCellsCessation of lifeCharacteristicsChemicalsCisplatinClinical TrialsComplete Blood CountCountryDNADNA CrosslinkingDNA DamageDNA Double Strand BreakDNA RepairDNA Repair DisorderDNA Repair GeneDataDeglutition DisordersDependenceDiagnosisDoseDouble Strand Break RepairDrug TargetingEnteral FeedingFamilyGene ExpressionGenerationsGenesGenetic TranscriptionGenomic InstabilityGenomicsGoalsGrowthHPV oropharyngeal cancerHuman PapillomavirusImmunohistochemistryIn VitroIncidenceIndividualKineticsLeadLengthLow Dose RadiationMalignant Epithelial CellMalignant neoplasm of cervix uteriMeasurementMeasuresModificationMolecularOropharyngealOropharyngeal NeoplasmsOropharyngeal Squamous Cell CarcinomaOutputPathway interactionsPatient SelectionPatientsPatternPopulationProliferatingProteinsQuality of lifeRNARadiationRadiation Dose UnitRadiation therapyResearchSeriesSpecificitySubgroupSurrogate MarkersSurvival AnalysisSurvival RateTestingTherapeuticTissuesToxic effectTranscriptional RegulationTreatment ProtocolsTreatment-related toxicityTumor Cell LineTumor VolumeUSP6 geneUnited StatesViralViral GenesViral GenomeViral MarkersVirus IntegrationWomanbiomarker selectioncancer cellcomorbiditydesignefficacy testingestablished cell lineexperimental studygene repressionhuman papilloma virus oropharyngeal squamous cell carcinomaimprovedin vivoinhibitorknock-downmalignant oropharynx neoplasmmembermenmouse modelneoplastic cellnew therapeutic targetpatient derived xenograft modelpleiotropismpreservationprogramsrecruitresponsesecondary endpointstandard of caretargeted treatmenttranscriptome sequencingtreatment strategytumortumor eradicationtumor growthtumor progressiontumor xenograftviral DNA
项目摘要
PROJECT SUMMARY/ABSTRACT:
During the past decade, oropharyngeal cancer surpassed cervical cancer, becoming the most common cancer
caused by human papillomavirus (HPV). Nearly 20,000 oropharyngeal cancer cases are diagnosed among men
and women in the United States annually. Despite favorable long-term survival, current non-targeted
cisplatin/radiation treatment protocols lead to significant treatment toxicities. De-escalating radiation doses with
alternative targeted therapies would be critical for limiting treatment-related toxicities and improving patient
quality of life. To address this, we propose to reduce the transcriptional output of viral genes and DNA damage
response (DDR) by reducing its dependence on a transcriptional co-regulator bromodomain protein, BRD4,
expressed in the oropharyngeal tissue. We propose that DDR deficiencies can be induced by second-generation
bromodomain-specific chemical inhibitors in HPV oropharyngeal tumors. This chemically induced DDR deficient
state delays the kinetics of DNA repair, thereby causing genomic instability. With tumors in this fragile state,
administering optimal radiation doses will result in genomic catastrophe leading to eradicating tumors. We
established that a first-generation inhibitor that targets both bromodomains BD1 and BD2 of BRD4 preferentially
reduced viral and DDR gene expression of a subset of HPV tumors, which harbored disrupted viral genomes
over non-disrupted viral genomes. However, pan-BD domain inhibition could give rise to pleiotropic effects. We
used second-generation domain-specific inhibitors introduced in 2020 on HPV tumor cell lines to refine the pan-
BD inhibition approach. We observed preferential domain-specific transcriptional regulation. While BD2 domain
inhibition downregulated DDR response in disrupted viral tumors, BD1 upregulated anti-viral gene expression in
non-disrupted viral tumors. These results guide us to postulate that patients selected upfront for disrupted viral
genomes can be matched for BD domain-specific inhibitor and de-escalated radiation treatments. We will use in
vitro and in vivo approaches to address a) efficacy of BD domain-specific inhibitors towards creating a DDR-
deficient state by measuring viral gene expression and quantifying DDR response kinetics, and test its on-target
efficacy in BRD4 knockdown and BD1 and BD2 domain-specific deleted tumor cells, b) Optimize the dose of
radiation sufficiently to preserve the efficacy of BD domain-specific inhibition in patient-derived xenograft mice
models with secondary endpoint analyses of survival, tumor volume growth, apoptosis, complete blood count
panel for toxicity and immunohistochemistry for proliferation and DNA repair proteins.
项目总结/摘要:
在过去的十年中,口咽癌超过宫颈癌,成为最常见的癌症
人乳头瘤病毒(HPV)近20,000例口咽癌病例在男性中被诊断出来
和美国妇女每年。尽管长期生存率良好,但目前的非靶向
顺铂/放射治疗方案导致显著的治疗毒性。降低辐射剂量,
替代性靶向治疗对于限制治疗相关毒性和改善患者预后至关重要。
生活质量为了解决这个问题,我们建议减少病毒基因的转录输出和DNA损伤
通过减少其对转录共调节因子溴结构域蛋白BRD 4的依赖,
在口咽组织中表达。我们认为,DDR缺陷可以由第二代
溴结构域特异性化学抑制剂在HPV口咽肿瘤中的应用这种化学诱导的DDR缺陷
状态延迟DNA修复的动力学,从而导致基因组不稳定。对于这种脆弱状态的肿瘤,
给予最佳的放射剂量将导致基因组灾难,从而导致根除肿瘤。我们
确定了优先靶向BRD 4的溴结构域BD 1和BD 2的第一代抑制剂
降低了一部分HPV肿瘤的病毒和DDR基因表达,这些肿瘤含有破坏的病毒基因组
而不是未被破坏的病毒基因组。然而,pan-BD结构域抑制可引起多效性效应。我们
使用2020年在HPV肿瘤细胞系上引入的第二代结构域特异性抑制剂,以完善泛
BD抑制方法。我们观察到优先域特异性转录调控。而BD 2结构域
抑制在破坏的病毒肿瘤中下调DDR反应,BD 1在破坏的病毒肿瘤中上调抗病毒基因表达。
未破坏的病毒肿瘤。这些结果指导我们假设,预先选择破坏病毒的患者
基因组可以与BD结构域特异性抑制剂和逐步降低的放射治疗相匹配。我们将在
a)BD结构域特异性抑制剂对产生DDR-1的功效,
通过测量病毒基因表达和量化DDR反应动力学来检测缺陷状态,并测试其靶向
在BRD 4敲低和BD 1和BD 2结构域特异性缺失的肿瘤细胞中的功效,B)优化
足以保持BD结构域特异性抑制在患者来源的异种移植小鼠中的功效的辐射
模型,次要终点分析包括生存期、肿瘤体积生长、细胞凋亡、全血细胞计数
毒性和增殖及DNA修复蛋白免疫组化检测。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gopal Iyer其他文献
Gopal Iyer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Dual targeting of Myc and apoptosis pathways for improved blood cancer treatment outcomes
Myc 和细胞凋亡途径的双重靶向可改善血癌治疗结果
- 批准号:
nhmrc : 1122829 - 财政年份:2017
- 资助金额:
$ 21.19万 - 项目类别:
Project Grants
Dual targeting of Myc and apoptosis pathways for improved blood cancer treatment outcomes
Myc 和细胞凋亡途径的双重靶向可改善血癌治疗结果
- 批准号:
nhmrc : GNT1122829 - 财政年份:2017
- 资助金额:
$ 21.19万 - 项目类别:
Project Grants
Development of detection and inducing method for single cell apoptosis and study on blood mineralization with these method
单细胞凋亡检测和诱导方法的建立及其对血液矿化的研究
- 批准号:
19770163 - 财政年份:2007
- 资助金额:
$ 21.19万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
A Study of Activation and Apoptosis of Peripheral Blood Mononuclear Cells and Lamina Propria Mononuclear Cells in Inflammatory Bowel Diseases
炎症性肠病外周血单个核细胞和固有层单个核细胞活化和凋亡的研究
- 批准号:
16590586 - 财政年份:2004
- 资助金额:
$ 21.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of Survivin in Blood Stem Cell Cycle and Apoptosis
生存素在血液干细胞周期和细胞凋亡中的作用
- 批准号:
6830337 - 财政年份:2004
- 资助金额:
$ 21.19万 - 项目类别:
Role of Survivin in Blood Stem Cell Cycle and Apoptosis
生存素在血液干细胞周期和细胞凋亡中的作用
- 批准号:
6912827 - 财政年份:2004
- 资助金额:
$ 21.19万 - 项目类别:
Role of Survivin in Blood Stem Cell Cycle and Apoptosis
生存素在血液干细胞周期和细胞凋亡中的作用
- 批准号:
7085451 - 财政年份:2004
- 资助金额:
$ 21.19万 - 项目类别:
Role of Survivin in Blood Stem Cell Cycle and Apoptosis
生存素在血液干细胞周期和细胞凋亡中的作用
- 批准号:
7261923 - 财政年份:2004
- 资助金额:
$ 21.19万 - 项目类别:
TCR-ζ EXPRESSION AND APOPTOSIS IN PERIPHRAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH HEAD AND NECK CANCER
头颈癌患者外周血单核细胞中 TCR-ζ 的表达和凋亡
- 批准号:
14571639 - 财政年份:2002
- 资助金额:
$ 21.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Donor Peripheral Blood Stem Cell Infusion and Apoptosis in Lymphocytes Induces Immunological Tolerance of Kidney Allografts in Rhesus Monkeys
供体外周血干细胞输注和淋巴细胞凋亡诱导恒河猴肾同种异体移植物的免疫耐受
- 批准号:
13470245 - 财政年份:2001
- 资助金额:
$ 21.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)